Population-based human papillomavirus infection and genotype distribution among women in rural areas of South Central Ethiopia.
Adult
Age Distribution
Alphapapillomavirus
/ classification
Cohort Studies
DNA, Viral
/ genetics
Early Detection of Cancer
Ethiopia
/ epidemiology
Female
Genotyping Techniques
/ methods
Health Promotion
Humans
Middle Aged
Multiplex Polymerase Chain Reaction
Papillomavirus Infections
/ epidemiology
Prevalence
Rural Health
Rural Population
Self-Testing
Specimen Handling
/ instrumentation
Butajira
HPV based screening
HPV epidemiology
cervical cancer
high-risk HPV
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
01 02 2021
01 02 2021
Historique:
received:
12
03
2020
revised:
22
07
2020
accepted:
12
08
2020
pubmed:
3
9
2020
medline:
25
6
2021
entrez:
3
9
2020
Statut:
ppublish
Résumé
In Ethiopia, cervical cancer is the second leading cause of morbidity and mortality from all cancers in women. Persistent infection with human papillomaviruses (HPV) plays a key role in the development of cervical intraepithelial neoplasia and invasive cervical cancer. To establish baseline data on the population-based prevalence of HPV infection and genotype distribution, we investigated cervical HPV epidemiology among rural women. This population-based study was conducted among rural women aged 30-49 years in Butajira, south-central Ethiopia. A total of 893 samples were tested from 1020 screened women. A self-sampling device (Evalyn Brush, Rovers, Oss, The Netherlands) was used and HPV presence and genotype was determined using multiplexed genotyping (MPG) by BSGP5+/6+ PCR with Luminex read out. The HPV positivity rate was 23.2% (95% CI: 23.54-22.86%) and 20.5% (95% CI = 20.79-20.21) and 10.3% (95% CI = 10.52-10.08) women were high-risk (hr- and low-risk (lr-) HPV positive, respectively. Fifty five (7.2%) of the women showed multiple hr-HPV infections. Age-specific hr-HPV infection peaked in the age-group 30- to 34 years old (58.6%) and decreased in 35-39, 40-44 and 45-49 years to 20.4%, 4.5% and 3.8% respectively. The top five prevalent hr-HPV genotypes were HPV16 (57.1%), 35 (20.3%), 52 (15.8%), 31 (14.1%), and 45 (9.6%) in the Butajira district. As a first population-based study in the country, our results can serve as valuable reference to guide nationwide cervical cancer screening and HPV vaccination programs in Ethiopia.
Substances chimiques
DNA, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
723-730Informations de copyright
© 2020 Union for International Cancer Control.
Références
Arbyn M, Weiderpass E, Bruni L, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Heal. 2019;8:e191-e203. https://doi.org/10.1016/S2214-109X(19)30482-6.
de Martel C, Georges D, Bray F, Ferlay JCG. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Heal. 2019;8(2):E180-E190. https://doi.org/10.1016/S2214-109X(19)30488-7.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87-108. https://doi.org/10.3322/caac.21262.
Bruni L, Albero G, Serrano B, Mena M, Gómez D, Muñoz J, Bosch FX de SS. ICO/IARC Information Centre on HPVand Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in Ethiopia. Summary Report. 2019 Accessed December 2, 2019.
Munger K, Baldwin A, Edwards KM, et al. Mechanisms of human papillomavirus-induced oncogenesis. J Virol. 2004;78(21):11451-11460. https://doi.org/10.1128/JVI.78.21.11451-11460.2004.
Racey CS, Withrow DR, Gesink D. Self-collected HPV testing improves participation in cervical cancer screening: a systematic review and meta-analysis. Can J Public Health. 2013;104(2):e159-e166.
Muñoz N. Valor del test del virus del papiloma humano en el diagnóstico y cribado de la neoplasia cervical. Med Clin (Barc). 2003;121(12):455-456. https://doi.org/10.1016/S0025-7753(03)73988-8.
Crow JM. HPV: the global burden. Nature. 2012;488(7413):S2-S3. https://doi.org/10.1038/488S2a.
Abreu ALP, Souza RP, Gimenes F, Consolaro MEL. A review of methods for detect human papillomavirus infection. Virol J. 2012;2012(9262):1-9. https://doi.org/10.1186/1743-422X-9-262.
Castellsagué X. Natural history and epidemiology of HPV infection and cervical cancer. Gynecol Oncol. 2008;110:4-7. https://doi.org/10.1016/j.ygyno.2008.07.045.
Clifford GM, Gallus S, Herrero R, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet (London, England). 2005;366(9490):991-998. https://doi.org/10.1016/S0140-6736(05)67069-9.
Baloch Z, Yuan T, Yindi S, et al. Prevalence of genital human papillomavirus among rural and urban populations in southern Yunnan province, China. Braz J Med Biol Res. 2016;49:1-7. https://doi.org/10.1590/1414-431X20165254.
Ogembo RK, Gona PN, Seymour AJ, Park HS, Bain PA, Maranda LOJ. Prevalence of human papillomavirus genotypes among African women with normal cervical cytology and neoplasia: a systematic review and meta-analysis. PLoS One. 2015;10(4):1-22. https://doi.org/10.1371/journal.pone.0122488.
Ruland R, Prugger C, Schiffer R, Regidor M, Lelle RJ. Prevalence of human papilloma virus infection in women in rural Ethiopia. Eur J Epidemiol. 2006;21:727-729. https://doi.org/10.1007/s10654-006-9055-4.
Leyh-Bannurah SR, Prugger C, de Koning MN, Goette HLR. Cervical human papillomavirus prevalence and genotype distribution among hybrid capture 2 positive women 15 to 64 years of age in the Gurage zone, rural Ethiopia. Infect Agents Cancer. 2014;2014(933):1-9.
Abate E, Aseffa A, El-Tayeb M, et al. Genotyping of human papillomavirus in paraffin embedded cervical tissue samples from women in Ethiopia and The Sudan. J Med Virol. 2013;85(2):282-287. https://doi.org/10.1002/jmv.23437.
Fanta BE. The distribution of human papilloma virus infection in women with cervical histological abnormalities from an area with high incidence of cervical cancer. Ethiop Med J. 2005;43(3):151-158.
Gizaw M, Teka B, Ruddies F, et al. Uptake of cervical cancer screening in Ethiopia by self-sampling HPV DNA compared to visual inspection with acetic acid: a cluster randomized trial. Cancer Prev Res. 2019;12(9):609-615. https://doi.org/10.1158/1940-6207.CAPR-19-0156.
Schmitt M, Dondog B, Waterboer T, Pawlita M. Homogeneous amplification of genital human alpha papillomaviruses by PCR using novel broad-spectrum GP5+ and GP6+ primers. J Clin Microbiol. 2008;46(3):1050-1059. https://doi.org/10.1128/JCM.02227-07.
Cuschieri K, Ronco G, Lorincz A, et al. Eurogin roadmap 2017: triage strategies for the management of HPV-positive women in cervical screening programs. Int J Cancer Eurogin. 2018;00:1-11. https://doi.org/10.1002/ijc.31261.
Krings A, Dunyo P, Pesic A, et al. Characterization of human papillomavirus prevalence and risk factors to guide cervical cancer screening in the North Tongu District, Ghana. PLoS One. 2019;16:1-19.
Zehbe I, Moeller H, Severini A, et al. Feasibility of self-sampling and human papillomavirus testing for cervical cancer screening in first nation women from Northwest Ontario, Canada: a pilot study. BMJ Open. 2011;1(1):1-12. https://doi.org/10.1136/bmjopen-2010-000030.
Jede F, Brandt T, Gedefaw M, et al. Home-based HPV self-sampling assisted by a cloud-based electronic data system: lessons learnt from a pilot community cervical cancer screening campaign in rural Ethiopia. Papillomavirus Res. 2020;9:100198. https://doi.org/10.1016/j.pvr.2020.100198.
Gizaw M, Teka B, Ruddies F, et al. Uptake of cervical cancer screening in Ethiopia by self-sampling HPV DNA compared to visual inspection with acetic acid: a cluster randomized trial. Cancer Prev Res (Phila). 2019;12(9):609-616. https://doi.org/10.1158/1940-6207.CAPR-19-0156.
Forman D, de Martel C, Lacey CJ, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30:F12-F23. https://doi.org/10.1016/j.vaccine.2012.07.055.
Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch FX, de Sanjose S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010;202(12):1789-1799. https://doi.org/10.1086/657321.
Guan P, Howell-Jones R, Li N, et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer. 2012;131(10):2349-2359. https://doi.org/10.1002/ijc.27485.
Denny L, Adewole I, Anorlu R, et al. Human papillomavirus prevalence and type distribution in invasive cervical cancer in sub-Saharan Africa. Int J Cancer. 2014;134(6):1389-1398. https://doi.org/10.1002/ijc.28425.
Castle PE, Schiffman M, Wheeler CM, Solomon D. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obs Gynecol. 2010;113(1):18-25. https://doi.org/10.1097/AOG.0b013e31818f5008.Evidence.
Jin Q, Shen K, Li H, Zhou XR, Huang HF, Leng JH, Zhang WH, Gong XM, Cheng XM, Suo L, Zhu YC, Lang JH, Lu CM, Wang P MW. Prevalence of human papillomavirus infection in women in Tibet autonomous region of China. 2009.
Khoo SP, Bhoo-pathy N, Yap SH, et al. Prevalence and sociodemographic correlates of cervicovaginal human papillomavirus (HPV) carriage in a cross-sectional, multiethnic, community-based female Asian population. Sex Transm Infect. 2018;94:276-282. https://doi.org/10.1136/sextrans-2017-053320.